A computational re-examination of 45,454 gut microbiomes across 141 studies identified 15 microbial taxa simultaneously enriched in aging and depleted in health. Cardiometabolic diseases showed the strongest overlap with aging-associated microbiome shifts, followed by colorectal cancer. Critically, over 50% of those 15 pathobionts belonged to oral-associated clades — Streptococcus, Veillonella, and Rothia — whose gut presence was reproducibly linked to seven cardiometabolic medications across two independent population cohorts totaling 6,029 subjects.
The finding reframes a long-standing interpretive problem in microbiome aging research. The "aging gut signature" may be substantially an artifact of medication exposure rather than biological senescence per se. Older adults disproportionately use cardiometabolic drugs — statins, antihypertensives, metformin — and these agents are increasingly recognized as modulators of microbial community composition. Oral bacteria translocating to the gut via medication-altered mucosal barriers or altered saliva flow could produce a spurious aging signal that conflates chronological age, disease burden, and polypharmacy.
The dataset size here is genuinely impressive, lending statistical credibility to an otherwise difficult-to-study confounder. Limitations include the study's observational, cross-sectional architecture — causal directionality between medications, oral microbes, and gut dysbiosis remains unresolved. Mechanistic work in longitudinal human cohorts is essential. Still, this is a paradigm-shifting methodological argument: aging microbiome studies that fail to control for medication use may be systematically misattributing drug effects to aging itself.
